Last updated: 2026-10-13 23:09:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
CalciMedica, Inc. (CALC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.12, with a market capitalisation of $8.67M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.09 to $36.00. This page covers its latest market performance, valuation, price trends and company information.
$8.67M | |
$1.22 | |
$2,807.00 | |
$1.09 | |
$1.21 | |
98.60K | |
76.02K | |
-- | |
$36.00 | |
$1.09 | |
-- | |
-- |
CalciMedica, Inc. (CALC) is trading at $1.11 in after-hours trading as of 2026-10-13 23:07:00, down 7.88% ($0.09) from the regular-session close of $1.21.
After-hours trading shows how investors are pricing CALC after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, CalciMedica, Inc. (CALC) moved from $1.60 to $1.12, representing a decline of 29.94% ($0.48).
The stock traded between $1.09 and $1.70 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 86.34 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.1%
CALC is currently trading at $1.12, placing it 0.1% of the way from its 52-week low of $1.09 to its 52-week high of $36.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CalciMedica, Inc. (CALC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.